ENO2 and myeloid sarcoma: The sensitivity of NSE for detecting MS activity is moderate; one large study found that serum NSE was not a strong predictor of disability progression in relapsing MS, but, in primary progressive MS patients, there was a moderate correlation between higher NSE levels and worse disability scores [16].